SEC Tracker
Get the app

Adaptin Bio APTN

Adaptin Bio FY 2024: net loss $161K; diluted EPS −$0.03

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Adaptin Bio reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$161KAgainst −$86K in FY 202310-K income statement, on EDGAR
  2. Diluted EPS−$0.03Against −$0.02 in FY 202310-K income statement, on EDGAR
  3. Cash and cash equivalents$34K+8870% from $380 in FY 202310-K balance sheet, on EDGAR
  4. Cash from operations−$182KAgainst −$81K in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Adaptin Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Artelo Biosciences ARTL public float $9M, Jun 30, 2025
  2. Bioxytran BIXT public float $9M, Jun 30, 2025
  3. Raphael Pharmaceutical RAPH public float $9M, Jun 30, 2025
  4. Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025
  5. TherapeuticsMD TXMD public float $9M, Jun 30, 2025